TITANIUM DIOXIDE(NANO)

TITANIUM DIOXIDE(NANO) was reported 141 times

These side effects are most commonly reported by patients taking TITANIUM DIOXIDE(NANO):

# Side effect Count
0 RASH 14
1 ACNE 10
2 ERYTHEMA 9
3 SUNBURN 9
4 DRY SKIN 8
5 MALIGNANT MELANOMA 8
6 HEADACHE 7
7 OFF LABEL USE 7
8 APPLICATION SITE ERYTHEMA 6
9 DERMATITIS 6
10 PAIN 6
11 PHOTOSENSITIVITY REACTION 6
12 SWELLING FACE 6
13 ARTHRALGIA 5
14 BLISTER 5
15 CONDITION AGGRAVATED 5
16 DEPRESSION 5
17 DIARRHOEA 5
18 DRUG INEFFECTIVE 5
19 FATIGUE 5
20 INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION 5
21 PRODUCT USE ISSUE 5
22 PRURITUS 5
23 PSORIASIS 5
24 SKIN EXFOLIATION 5
25 XEROSIS 5
26 APPLICATION SITE PAIN 4
27 BASAL CELL CARCINOMA 4
28 DRUG HYPERSENSITIVITY 4
29 DRY EYE 4
30 ECZEMA 4
31 HYPERSENSITIVITY 4
32 INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 4
33 MALAISE 4
34 PAIN OF SKIN 4
35 SKIN BURNING SENSATION 4
36 SOMNOLENCE 4
37 THERAPEUTIC RESPONSE UNEXPECTED 4
38 ANXIETY 3
39 ASTHENIA 3
40 BURNING SENSATION 3
41 CHEILITIS 3
42 COUGH 3
43 HEART RATE INCREASED 3
44 HOSPITALISATION 3
45 ILLNESS 3
46 INTENTIONAL PRODUCT MISUSE 3
47 MOOD ALTERED 3
48 NAUSEA 3
49 PIGMENTATION DISORDER 3
50 RASH ERYTHEMATOUS 3
51 SENSITIVE SKIN 3
52 SKIN DISCOLOURATION 3
53 SKIN HYPERPIGMENTATION 3
54 SKIN IRRITATION 3
55 UNDERDOSE 3
56 URTICARIA 3
57 WEIGHT DECREASED 3
58 ABDOMINAL DISCOMFORT 2
59 ABDOMINAL PAIN UPPER 2
60 ABNORMAL LOSS OF WEIGHT 2
61 ACNE CYSTIC 2
62 ADVERSE EVENT 2
63 APPLICATION SITE DISCHARGE 2
64 APPLICATION SITE DISCOLOURATION 2
65 APPLICATION SITE EXFOLIATION 2
66 BACK PAIN 2
67 CHOLECYSTITIS ACUTE 2
68 CHOLESTASIS 2
69 CONTUSION 2
70 DEATH 2
71 DECREASED APPETITE 2
72 DRUG INTOLERANCE 2
73 DRY MOUTH 2
74 DYSPHAGIA 2
75 DYSPNOEA 2
76 EYE IRRITATION 2
77 EYE PAIN 2
78 FALL 2
79 GASTROINTESTINAL HAEMORRHAGE 2
80 HYPERHIDROSIS 2
81 IMMUNE SYSTEM DISORDER 2
82 IMMUNE-MEDIATED HEPATITIS 2
83 INFECTION 2
84 INFLAMMATION 2
85 INTENTIONAL PRODUCT USE ISSUE 2
86 INTENTIONAL UNDERDOSE 2
87 JOINT SWELLING 2
88 LENTIGO 2
89 LUNG NEOPLASM MALIGNANT 2
90 MELANOCYTIC NAEVUS 2
91 MILIARIA 2
92 MIOSIS 2
93 MUSCLE SPASMS 2
94 MYALGIA 2
95 OVERDOSE 2
96 PAIN IN EXTREMITY 2
97 PERIPHERAL SWELLING 2
98 PNEUMONIA 2
99 PRODUCT ADMINISTERED AT INAPPROPRIATE SITE 2
100 PRODUCT DOSE OMISSION ISSUE 2
101 PRODUCT QUALITY ISSUE 2
102 PSORIATIC ARTHROPATHY 2
103 PYREXIA 2
104 RASH MACULAR 2
105 RASH PAPULAR 2
106 SEBORRHOEIC KERATOSIS 2
107 SEIZURE 2
108 SKIN HAEMORRHAGE 2
109 SKIN LESION 2
110 SKIN WARM 2
111 SQUAMOUS CELL CARCINOMA 2
112 SWELLING 2
113 TACHYCARDIA 2
114 THERAPEUTIC PRODUCT EFFECT INCOMPLETE 2
115 ABDOMINAL DISTENSION 1
116 ABDOMINAL PAIN 1
117 ACCIDENTAL EXPOSURE TO PRODUCT 1
118 ACTINIC KERATOSIS 1
119 ACUTE KIDNEY INJURY 1
120 ACUTE PULMONARY OEDEMA 1
121 ADDISON^S DISEASE 1
122 ALANINE AMINOTRANSFERASE INCREASED 1
123 ALOPECIA 1
124 AMMONIA INCREASED 1
125 ANAEMIA 1
126 ANAL FISTULA 1
127 ANGIOPATHY 1
128 APPLICATION SITE HAEMORRHAGE 1
129 APPLICATION SITE IRRITATION 1
130 APPLICATION SITE NODULE 1
131 APPLICATION SITE PRURITUS 1
132 APPLICATION SITE RASH 1
133 APPLICATION SITE SCAB 1
134 APPLICATION SITE SWELLING 1
135 APPLICATION SITE VESICLES 1
136 ARTHROPOD STING 1
137 ASCITES 1
138 ASPARTATE AMINOTRANSFERASE INCREASED 1
139 ASPIRATION 1
140 ASTHMA 1
141 ATRIAL FIBRILLATION 1
142 B-CELL SMALL LYMPHOCYTIC LYMPHOMA 1
143 BACK DISORDER 1
144 BACTERIAL INFECTION 1
145 BALANCE DISORDER 1
146 BLOOD CALCIUM INCREASED 1
147 BLOOD CHOLESTEROL INCREASED 1
148 BLOOD CREATINE PHOSPHOKINASE INCREASED 1
149 BLOOD GLUCOSE INCREASED 1
150 BLOOD PRESSURE DECREASED 1
151 BLOOD PRESSURE INCREASED 1
152 BRONCHOSPASM 1
153 C-REACTIVE PROTEIN 1
154 CARDIAC MURMUR 1
155 CARDIOMEGALY 1
156 CATARACT OPERATION 1
157 CEREBROVASCULAR ACCIDENT 1
158 CHEMICAL BURN 1
159 CHEMICAL BURNS OF EYE 1
160 CHEST PAIN 1
161 CONFUSIONAL STATE 1
162 CONJUNCTIVITIS ALLERGIC 1
163 CONSTIPATION 1
164 CONTRAINDICATED PRODUCT ADMINISTERED 1
165 CONVULSION 1
166 COVID-19 1
167 DEHYDRATION 1
168 DERMATITIS CONTACT 1
169 DERMATITIS PSORIASIFORM 1
170 DIABETES MELLITUS 1
171 DISABILITY 1
172 DISCOMFORT 1
173 DISEASE PROGRESSION 1
174 DISEASE RECURRENCE 1
175 DROOLING 1
176 DRUG ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE 1
177 DRUG EFFECT INCOMPLETE 1
178 DRUG EFFECT LESS THAN EXPECTED 1
179 DRUG EFFECTIVE FOR UNAPPROVED INDICATION 1
180 DRUG INEFFECTIVE FOR UNAPPROVED INDICATION 1
181 DYSPEPSIA 1
182 DYSPNOEA EXERTIONAL 1
183 ENCEPHALITIS 1
184 ENDOMETRIOSIS 1
185 EPISTAXIS 1
186 EXPIRED PRODUCT ADMINISTERED 1
187 EXPOSURE TO MOULD 1
188 EYE OEDEMA 1
189 FACIAL ASYMMETRY 1
190 FEELING HOT 1
191 FLATULENCE 1
192 FLUSHING 1
193 FREQUENT BOWEL MOVEMENTS 1
194 FUNGAL OESOPHAGITIS 1
195 GAIT DISTURBANCE 1
196 GASTRIC ULCER 1
197 GASTROENTERITIS VIRAL 1
198 GASTROINTESTINAL DISORDER 1
199 GASTROINTESTINAL MELANOSIS 1
200 GENERAL PHYSICAL HEALTH DETERIORATION 1
201 GLOSSODYNIA 1
202 GUTTATE PSORIASIS 1
203 HAEMANGIOMA 1
204 HAEMATURIA 1
205 HAEMORRHAGE 1
206 HAIR COLOUR CHANGES 1
207 HEAVY EXPOSURE TO ULTRAVIOLET LIGHT 1
208 HEPATITIS 1
209 HOT FLUSH 1
210 HYPERAESTHESIA 1
211 HYPEREOSINOPHILIC SYNDROME 1
212 HYPERGLYCAEMIA 1
213 HYPERKERATOSIS 1
214 HYPERSOMNIA 1
215 HYPERTENSION 1
216 HYPERTRIGLYCERIDAEMIA 1
217 HYPOPHAGIA 1
218 HYPOTENSION 1
219 IMMUNOSUPPRESSION 1
220 INCORRECT DOSAGE ADMINISTERED 1
221 INCORRECT DRUG ADMINISTRATION DURATION 1
222 INCORRECT PRODUCT ADMINISTRATION DURATION 1
223 INCORRECT PRODUCT STORAGE 1
224 INFLUENZA LIKE ILLNESS 1
225 INJECTION SITE DRYNESS 1
226 INJECTION SITE HAEMORRHAGE 1
227 INJECTION SITE MASS 1
228 INJECTION SITE PAIN 1
229 INJECTION SITE PRURITUS 1
230 INJECTION SITE REACTION 1
231 INJECTION SITE SWELLING 1
232 INJURY ASSOCIATED WITH DEVICE 1
233 INSOMNIA 1
234 INTENTIONAL DOSE OMISSION 1
235 JAUNDICE 1
236 JOINT WARMTH 1
237 LIP DRY 1
238 LIVER FUNCTION TEST INCREASED 1
239 LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES 1
240 LOW DENSITY LIPOPROTEIN INCREASED 1
241 MALIGNANT MELANOMA IN SITU 1
242 MENINGITIS VIRAL 1
243 METASTATIC MALIGNANT MELANOMA 1
244 MIGRAINE 1
245 MOBILITY DECREASED 1
246 MOUTH ULCERATION 1
247 MUSCLE DISORDER 1
248 MUSCULAR WEAKNESS 1
249 MUSCULOSKELETAL DISCOMFORT 1
250 MUSCULOSKELETAL STIFFNESS 1
251 MYELOSUPPRESSION 1
252 NAIL DISORDER 1
253 NASAL CONGESTION 1
254 NASAL OEDEMA 1
255 NASOPHARYNGITIS 1
256 NEPHROLITHIASIS 1
257 NERVE INJURY 1
258 NEUTROPENIA 1
259 NODULE 1
260 OCULAR HYPERAEMIA 1
261 OCULAR ICTERUS 1
262 OEDEMA 1
263 OESOPHAGEAL ULCER 1
264 ORGANISING PNEUMONIA 1
265 OSTEOMYELITIS 1
266 OXYGEN SATURATION DECREASED 1
267 PALPITATIONS 1
268 PETECHIAE 1
269 PINGUECULA 1
270 PLASMA CELL MYELOMA 1
271 POOR QUALITY PRODUCT ADMINISTERED 1
272 PRE-EXISTING CONDITION IMPROVED 1
273 PRODUCT ADMINISTRATION INTERRUPTED 1
274 PRODUCT DOSE OMISSION 1
275 PRODUCT STORAGE ERROR 1
276 PRODUCT USE IN UNAPPROVED INDICATION 1
277 PRODUCTIVE COUGH 1
278 PSYCHOTIC DISORDER 1
279 PULMONARY EMBOLISM 1
280 PULMONARY HAEMORRHAGE 1
281 PYOGENIC GRANULOMA 1
282 RALES 1
283 RASH MACULO-PAPULAR 1
284 RASH PRURITIC 1
285 RECTAL HAEMORRHAGE 1
286 RED BLOOD CELL COUNT INCREASED 1
287 RESPIRATORY DISORDER 1
288 RESPIRATORY FAILURE 1
289 RETINAL HAEMORRHAGE 1
290 SCAB 1
291 SCAR 1
292 SCLERODERMA 1
293 SCRATCH 1
294 SEBORRHOEIC DERMATITIS 1
295 SELF-INJURIOUS IDEATION 1
296 SEPSIS 1
297 SKIN ATROPHY 1
298 SKIN CANCER 1
299 SKIN DEPIGMENTATION 1
300 SKIN DISCOMFORT 1
301 SKIN DISORDER 1
302 SKIN MASS 1
303 SKIN PLAQUE 1
304 SKIN REACTION 1
305 SKIN TIGHTNESS 1
306 SLEEP DISORDER 1
307 SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION 1
308 SOLAR DERMATITIS 1
309 SPINAL DISORDER 1
310 STOMATITIS 1
311 SUICIDAL IDEATION 1
312 SYSTEMIC LUPUS ERYTHEMATOSUS 1
313 TACHYPNOEA 1
314 THERAPEUTIC PRODUCT INEFFECTIVE 1
315 THIRST 1
316 TONGUE ULCERATION 1
317 TRIGGER FINGER 1
318 TYPE 2 DIABETES MELLITUS 1
319 UPPER RESPIRATORY TRACT INFECTION 1
320 URINARY INCONTINENCE 1
321 URINARY RETENTION 1
322 VASCULAR INJURY 1
323 VASCULITIS 1
324 VISION BLURRED 1
325 VITILIGO 1
326 VITREOUS HAEMORRHAGE 1
327 VOMITING 1
328 VON WILLEBRAND^S DISEASE 1
329 WALKING DISABILITY 1
330 WEIGHT INCREASED 1
331 WOUND 1